Hansoh Biomedical R&d Company

This early-stage study tests a new drug called HS-20122 in adults with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. About 1,050 participants will receive the drug intravenously and be closel…

This early-phase study tests a new drug called HS-20093 in 40 people with advanced stomach or gastroesophageal junction cancer that has not responded to standard treatments. The drug is designed to attach to a protein on cancer cells and deliver a toxic payload to kill them. The …

This study tests a new drug called HS-20089 against standard chemotherapy in people with ovarian, fallopian tube, or primary peritoneal cancer that no longer responds to platinum-based treatments. About 468 women will be randomly assigned to receive either HS-20089 or a doctor-ch…

This study tests two experimental drugs, HS-20093 and HRS-5041, together in men with advanced prostate cancer that has stopped responding to standard hormone therapy. The goal is to find the safest dose and understand side effects. About 63 participants will take part in this ear…

This study tests a new drug combination (HS-20110) in people with advanced colorectal cancer that has not responded to standard treatments. The goal is to find the safest dose and see if it can shrink tumors. About 500 adults will take part in this early-phase trial across multip…

This early-stage trial tests a new drug called HS-20110 in 475 adults with advanced solid tumors that have not responded to other treatments. The main goals are to find the safest dose and see if the drug can shrink tumors. Researchers will also monitor side effects and how long …

This study looks at how the antifungal drug itraconazole changes the levels of the cancer drug HS-20093 in the body. It involves 18 adults with advanced solid tumors who have not responded to or cannot tolerate standard treatments. The goal is to understand the interaction to hel…